false
0001318641
0001318641
2021-11-18
2021-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 18, 2021
Statera Biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-32954
|
20-0077155
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
| |
2537 Research Boulevard, Suite 201
Fort Collins, CO 80526
|
|
|
(Address of Principal Executive Offices and zip code)
|
| |
|
|
| |
(888) 613-8802
|
|
|
(Registrant's Telephone Number, Including Area Code)
|
Securities registered or to be registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common stock, par value $0.005
|
STAB
|
NASDAQ Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| |
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure
On December 1, 2021, Statera Biopharma, Inc. (the “Company”) issued a press release announcing certain recent regulatory developments. A copy of the press release issued by the Company is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 of Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
Number
|
Description
|
| |
|
|
99.1
|
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Statera Biopharma, Inc.
|
|
|
|
|
|
|
|
Date: December 1, 2021
|
By:
|
/s/ Cozette McAvoy
|
|
|
|
Name:
|
Cozette McAvoy
|
|
|
|
Title:
|
Chief Legal Officer
|
|